Correction MAR label – SelectImmune Pharma’s CEO recruited to new position

The correction refers to the MAR label. This press release should be without the MAR label. Selectimmune Pharma’s CEO Ann Gidner will leave SelectImmune Pharma, having accepted an offer from a non-competing Life-Science company. Ann Gidner will remain in the CEO role during the notice period of one month. The board has initiated the recruitment of a new CEO for the company.

”We are grateful for the contributions of Ms Gidner and wish her all the best in her next position,” says Catharina Svanborg, Chairman of the board, SelectImmune Pharma.

For more information, please contact:

Catharina Svanborg

Chairman of the board SelectImmune Pharma AB

Phone: +46 709 42 65 49

E-mail: catharina.svanborg@med.lu.se

SelectImmune Pharma is a pharmaceutical company whose shares are traded on the Spotlight Stock Market. The company goal is to develop new immunotherapies, which act as immune enhancers and offer alternatives to antibiotics.

Bacterial infections affect large parts of the population and are becoming increasingly difficult to treat due to increasing antibiotic resistance. SelectImmune Pharma develops immunotherapies that can supplement or replace antibiotics. Urinary tract infections (UVI) are one of the world’s most common infectious diseases, affecting about 150 million people each year. The need for alternative treatments for bacterial infections is currently very large as are potential markets.